Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems; InAAVate, a proprietary "plug and play' dual-plasmid system for transient transfection, as well as a standard triple transfection system for AAV-based gene therapies. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.
Frequently asked questions
What sector does Oxford Biomedica plc (OXBDF) operate in?
Oxford Biomedica plc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Oxford Biomedica plc (OXBDF) current stock price?
As of the latest data, Oxford Biomedica plc stock price is $7.25, with a previous close of $7.25.
What is Oxford Biomedica plc (OXBDF) current market capitalization?
Oxford Biomedica plc market cap is approximately 877.64 million.
What is Oxford Biomedica plc (OXBDF) Earnings Per Share (EPS)?
The trailing EPS is -$0.43.
Does Oxford Biomedica plc (OXBDF) pay dividends?
No. Oxford Biomedica plc does not pay a dividend.
When is Oxford Biomedica plc (OXBDF) next earnings report?
Oxford Biomedica plc is expected to release its next earnings report on June 30, 2026.
What is Oxford Biomedica plc (OXBDF) beta (volatility) score?
Oxford Biomedica plc has a beta of 1.106, meaning its volatility is roughly in line with the market.
